Kurozumi et al. considered a CD8 + cell count > 25 in their cohort of 126 HER2 + breast cancer patients who underwent neoadjuvant therapy as ‘high CD8 + TIL expression’ and reported a positive correlation with pCR [32]. This evidence concerns the gene CD8A and breast carcinoma.